GlassScriptPhysician profile
William B Chung
NPI 1578579504
$25,858.88
in general payments reported to CMS, 2019-2025
19 companies · $5,163 in 2025
The $5,163 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $366 · 2021: $3,340 · 2022: $8,405 · 2023: $2,479 · 2024: $5,717 · 2025: $5,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,830 · Travel and Lodging: $3,828 · Consulting Fee: $2,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,830.31 |
| Travel and Lodging | $3,828.49 |
| Consulting Fee | $2,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $10,995.98 | 2021-2025 | Corevalve Evolut R, Hawkone, Everflex |
| Abbott Laboratories | $6,795.47 | 2019-2025 | Triclip, Mitraclip, Tendyne |
| Edwards Lifesciences Corporation | $6,185.17 | 2019-2025 | Evoque, Sapien 3 Ultra Resilia, Pascal |
| W. L. Gore & Associates, INC. | $363.89 | 2023 | Gore Cardioform Septal Occluder |
| Esperion Therapeutics, INC. | $358.18 | 2021-2025 | Nexletol |
| Kestra Medical Technology Services, INC. | $247.22 | 2022-2025 | Assure Wcd |
| Novo Nordisk INC | $189.37 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $165.70 | 2023-2025 | Rotapro, Ekosonic, Avvigo Guidance System |
| Medtronic Vascular, INC. | $137.96 | 2019 | |
| Philips North America LLC | $102.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $75.43 | 2023-2024 | |
| Cardiva Medical, INC. | $57.92 | 2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade 5f Vcs |
| Impulse Dynamics (USA) INC. | $38.10 | 2021-2022 | |
| Glaxosmithkline, LLC. | $31.19 | 2023 | Arexvy, Shingrix |
| Penumbra, INC. | $26.73 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $24.28 | 2025 | |
| Biosense Webster, INC. | $23.18 | 2024 | Nuvision Ice Catheter |
| Amgen INC. | $22.96 | 2025 | Repatha |
| Pfizer INC. | $17.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.